Kestra is a medical technology company that develops and markets the ASSURE Wearable Cardioverter Defibrillator (WCD), a garment-based device designed to protect patients at risk of sudden cardiac arrest. The ASSURE WCD continuously monitors heart rhythms and automatically delivers therapeutic shocks if it detects life-threatening arrhythmias. The system includes a mobile application for patients and a remote monitoring platform for clinicians to receive real-time alerts. Kestra targets patients who require temporary protection while recovering from heart attacks or cardiomyopathy before they become eligible for permanent implantable defibrillators. Kestra leases the ASSURE WCD to patients and bills third-party payors, including Medicare and private insurers, based on the duration of use. The company utilizes a reusable hardware model where core devices are reconditioned for new patients, allowing each unit to serve approximately three patients per year. Kestra sells directly to cardiologists in the U.S. through a dedicated sales force and a network of specialists who manage patient fitting. The company's growth strategy focuses on capturing market share by improving patient compliance and reducing false alarm rates compared to legacy products. Kestra is also expanding its in-network insurance coverage, which reached the low-80% range in FY26, and is pursuing regulatory approval to enter Western European markets.